Literature DB >> 12525619

Peripheral blood cytotoxic gammadelta T lymphocytes from patients with human immunodeficiency virus type 1 infection and AIDS lyse uninfected CD4+ T cells, and their cytocidal potential correlates with viral load.

Sardar T A K Sindhu1, Rasheed Ahmad, Richard Morisset, Ali Ahmad, José Menezes.   

Abstract

Progression of human immunodeficiency virus type 1 (HIV-1) infection in humans is marked by declining CD4+-T-cell counts and increasing virus load (VL). Cytotoxic T lymphocytes (CTL) play an important role in the lysis of HIV-infected cells, especially during the early phase of asymptomatic infection. CTL responses in the later phase of disease progression may not be as effective since progressors with lower CD4+-T-cell counts have consistently higher VL despite having elevated CTL counts. We hypothesized that, apart from antiviral effects, some CTL might also contribute to AIDS pathogenesis by depleting CD4+ T cells and that this CTL activity may correlate with the VL in AIDS patients. Therefore, a cross-sectional study of 31 HIV-1-infected patients at various clinical stages was carried out. Purified CTL from these donors as well as HIV-seronegative controls were used as effectors against different human cell targets by using standard 51Cr release cytolytic assays. A direct correlation between VL and CTL-mediated, major histocompatibility complex (MHC)-unrestricted lysis of primary CD4+-T-cell, CEM.NKR, and K562 targets was observed. CD4+-T-cell counts and duration of infection also correlated with MHC-unrestricted cytolytic activity. Our data clearly show that gammadelta CTL are abnormally expanded in the peripheral blood of HIV-infected patients and that the Vdelta1 subset of gammadelta T cells is the main effector population responsible for this type of cytolysis. The present data suggest that gammadelta CTL can contribute to the depletion of bystander CD4+ T cells in HIV-infected patients as a parallel mechanism to HIV-associated immunopathogenesis and hence expedite AIDS progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525619      PMCID: PMC140951          DOI: 10.1128/jvi.77.3.1848-1855.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease.

Authors:  A M Gómez; F M Smaill; K L Rosenthal
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

2.  Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.

Authors:  Y Tanaka; C T Morita; Y Tanaka; E Nieves; M B Brenner; B R Bloom
Journal:  Nature       Date:  1995-05-11       Impact factor: 49.962

3.  Early activation of human V gamma 9V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands.

Authors:  F Lang; M A Peyrat; P Constant; F Davodeau; J David-Ameline; Y Poquet; H Vié; J J Fournié; M Bonneville
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

4.  Lysis of CD4+ lymphocytes by non-HLA-restricted cytotoxic T lymphocytes from HIV-infected individuals.

Authors:  M D Grant; F M Smaill; K L Rosenthal
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

5.  Nonpeptide ligands for human gamma delta T cells.

Authors:  Y Tanaka; S Sano; E Nieves; G De Libero; D Rosa; R L Modlin; M B Brenner; B R Bloom; C T Morita
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

6.  Changes in the cytotoxic T-cell repertoire of HIV-1-infected individuals: relationship to disease progression.

Authors:  M D Grant; F M Smaill; K Laurie; K L Rosenthal
Journal:  Viral Immunol       Date:  1993       Impact factor: 2.257

7.  CDR3-independent gamma delta V delta 1+ T cell expansion in the peripheral blood of HIV-infected persons.

Authors:  S Boullier; M Cochet; F Poccia; M L Gougeon
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

8.  Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells.

Authors:  C T Morita; E M Beckman; J F Bukowski; Y Tanaka; H Band; B R Bloom; D E Golan; M B Brenner
Journal:  Immunity       Date:  1995-10       Impact factor: 31.745

9.  Cytotoxic T-lymphocytes that kill autologous CD4+ lymphocytes are associated with CD4+ lymphocyte depletion in HIV-1 infection.

Authors:  M D Grant; F M Smail; K L Rosenthal
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-06

10.  V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer.

Authors:  J F Bukowski; C T Morita; Y Tanaka; B R Bloom; M B Brenner; H Band
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

View more
  15 in total

1.  Association between peripheral γδ T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa.

Authors:  Natalie N Zheng; M Juliana McElrath; Papa Salif Sow; Andrew Mesher; Stephen E Hawes; Joshua Stern; Geoffrey S Gottlieb; Stephen C De Rosa; Nancy B Kiviat
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

2.  Targeting γδ T cells for immunotherapy of HIV disease.

Authors:  C David Pauza; David J Riedel; Bruce L Gilliam; Robert R Redfield
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

3.  Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy.

Authors:  Michael A Poles; Shady Barsoum; Wenjie Yu; Jian Yu; Patricia Sun; Jeanine Daly; Tian He; Saurabh Mehandru; Andrew Talal; Martin Markowitz; Arlene Hurley; David Ho; Linqi Zhang
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Virus load correlates inversely with the expression of cytotoxic T lymphocyte activation markers in HIV-1-infected/AIDS patients showing MHC-unrestricted CTL-mediated lysis.

Authors:  S T A K Sindhu; R Ahmad; M Blagdon; A Ahmad; E Toma; R Morisset; J Menezes
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

Review 5.  γδ T Cells in HIV Disease: Past, Present, and Future.

Authors:  C David Pauza; Bhawna Poonia; Haishan Li; Cristiana Cairo; Suchita Chaudhry
Journal:  Front Immunol       Date:  2015-01-30       Impact factor: 7.561

6.  Low immunogenicity of neural progenitor cells differentiated from induced pluripotent stem cells derived from less immunogenic somatic cells.

Authors:  Pengfei Liu; Shubin Chen; Xiang Li; Li Qin; Ke Huang; Lihui Wang; Wenhao Huang; Shengbiao Li; Bei Jia; Mei Zhong; Guangjin Pan; Jinglei Cai; Duanqing Pei
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

Review 7.  Human gamma delta T cells: candidates for the development of immunotherapeutic strategies.

Authors:  Susann Beetz; Lothar Marischen; Dieter Kabelitz; Daniela Wesch
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

8.  CD3ε Expression Defines Functionally Distinct Subsets of Vδ1 T Cells in Patients With Human Immunodeficiency Virus Infection.

Authors:  Pádraic J Dunne; Christina O Maher; Michael Freeley; Katie Dunne; Andreea Petrasca; Judy Orikiiriza; Margaret R Dunne; Derval Reidy; Siobhan O'Dea; Aisling Loy; Jim Woo; Aideen Long; Thomas R Rogers; Fiona Mulcahy; Derek G Doherty
Journal:  Front Immunol       Date:  2018-05-02       Impact factor: 7.561

9.  MIP-1α Expression Induced by Co-Stimulation of Human Monocytic Cells with Palmitate and TNF-α Involves the TLR4-IRF3 Pathway and Is Amplified by Oxidative Stress.

Authors:  Sardar Sindhu; Nadeem Akhter; Ajit Wilson; Reeby Thomas; Hossein Arefanian; Ashraf Al Madhoun; Fahd Al-Mulla; Rasheed Ahmad
Journal:  Cells       Date:  2020-07-29       Impact factor: 6.600

10.  The Cooperative Induction of CCL4 in Human Monocytic Cells by TNF-α and Palmitate Requires MyD88 and Involves MAPK/NF-κB Signaling Pathways.

Authors:  Sardar Sindhu; Shihab Kochumon; Steve Shenouda; Ajit Wilson; Fahd Al-Mulla; Rasheed Ahmad
Journal:  Int J Mol Sci       Date:  2019-09-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.